FDA Phase IV Enforcement Powers Needed In PDUFA III, Rep. Stupak Says

FDA's experience with Bristol-Myers Squibb's Serzone is one indication that the agency needs greater enforcement power for postmarketing commitments, Rep. Bart Stupak (D-Mich.) said